Fingolimod is an oral drug for the escalation of treatment of relapsing-remitting multiple sclerosis in patients with persistent disease activity on first-line drugs or in patients with rapidly progressive severe relapsing-remitting multiple sclerosis. An ultra-high-performance liquid chromatography-tandem mass spectrometry method for determining the concentrations of fingolimod and its active metabolite fingolimod phosphate in whole blood has been developed and validated. The advantages of this method are the easy, fast and cheap sample preparation using protein precipitation from blood with a mixture of acetonitrile-methanol (40:60, v/v). Chromatographic separation was performed on a ultra-high performance liquid chromatography BEH C18 1.7 μm (100 × 2.1 mm) column. Two modes of ionization, electrospray ionization and atmospheric pressure chemical ionization, were tested and compared. For validation, the electrospray ionization mode was chosen. As internal standard, isotopically labeled fingolimod-D4 was used to quantify the analytes. The method was validated according to the rules of the European Medicines Agency. The coefficients of variation for fingolimod were in the range of 1.13-11.88%, and the recovery was 98.80-106.00%. The coefficients of variation for fingolimod phosphate were in the range of 2.73-9.31%, and the recovery was 90.08-107.00%. The method is quite easy and fast and can be used for routine analysis.

Department of Children Neurology Department of Neurology University Hospital Ostrava Ostrava Czech Republic

Department of Clinical Pharmacology Faculty of Medicine University of Ostrava Ostrava Czech Republic

Department of Clinical Pharmacology Institute of Laboratory Medicine University Hospital Ostrava Ostrava Czech Republic

See more in PubMed

Brozmanova, H., Perinova, I., Halvova, P., & Grundmann, M. (2010). Liquid chromatography‐tandem mass spectrometry method for simultaneous determination of cyclosporine A and its three metabolites AM1, AM9 and AM4N in whole blood and isolated lymphocytes in renal transplant patients. Journal of Separation Science, 33, 2287–2293. https://doi.org/10.1002/jssc.201000185

David, O. J., Berwick, A., Pezous, N., Lang, M., Tiel‐wilck, K., Ziemssen, T., Hara, P., Li, H., & Schmouder, R. (2018). Determination of seminal concentration of fingolimod and fingolimod‐phosphate in multiple sclerosis patients receiving chronic treatment with fingolimod. Clinical Pharmacology in Drug Development, 7(2), 217–221. https://doi.org/10.1002/cpdd.424

Emotte, C., Deglave, F., Heudi, O., Picard, F., & Kretz, O. (2012). Fast simultaneous quantitative analysis of FTY720 and its metabolite FTY720‐P in human blood by on‐line solid phase extraction coupled with liquid chromatography‐tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 58, 102–112. https://doi.org/10.1016/j.jpba.2011.09.021

Ferreirós, N., Labocha, S., Schröder, M., Radeke, H. H., & Geisslinger, G. (2012). LC‐MS/MS determination of FTY720 and FTY720‐phosphate in murine intracellular compartments and human plasma. Journal of Chromatography B, 887‐888, 122–127. https://doi.org/10.1016/j.jchromb.2012.01.023

Guideline on bioanalytical method validation. (2015). European Medicines Agency. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf

Hall, T. G., Smukste, I., Bresciano, K. R., Wang, Y., McKearn, D., & Savage, R. E. (2012). Identifying and overcoming matrix effects in drug discovery and development. IntechOpen.

Kumar, R. S., Balasubramanian, H., Lakshminarayanan, K., Mullapudi, S. K., Srinivas, K., & Sagyam, R. R. (2019). A systematic approach for reversed phase liquid chromatographic method development of fingolimod hydrochloride via design augmentation. Arabian Journal of Chemistry, 12(8), 3289–3301. https://doi.org/10.1016/j.arabjc.2015.08.012

MedChemExpress—Master of Bioactive Molecules. (2013a). Fingolimod. https://www.medchemexpress.com/fingolimod.html

MedChemExpress—Master of Bioactive Molecules. (2013b). Fingolimod‐phosphate. https://www.medchemexpress.com/fingolimod-phosphate.html

Osman, I. A., & Basalious, E. B. (2016). Method development and validation for fingolimod by HPLC/UV in immediate‐release oral capsule and study the effect of excipients on solubility and dissolution behavior. Journal of Analytical & Pharmaceutical Research, 2(1), 00008. https://doi.org/10.15406/japlr.2016.02.00008

Pesakova, V., Brozmanova, H., Sistik, P., Kusnirikova, Z., Kacirova, I., & Grundmann, M. (2023). Liquid chromatography‐tandem mass spectrometry method for determination of total and free teriflunomide concentration in serum of patients with multiple sclerosis. Journal of Pharmaceutical and Biomedical Analysis, 224, 115173. https://doi.org/10.1016/j.jpba.2022.115173

Salm, P., Warnholtz, C. H. R., Lynch, S. V., & Taylor, P. J. (2006). Measurement and stability of FTY720 in human whole blood by high‐performance liquid chromatography‐atmospheric pressure chemical ionization‐tandem mass spectrometry. Journal of Chromatography B, 843, 157–163. https://doi.org/10.1016/j.jchromb.2006.05.026

Sistik, P., Urinovska, R., Brozmanova, H., Kacirova, I., Silhan, P., & Lemr, K. (2016). Fast simultaneous LC/MS/MS determination of 10 active compounds in human serum for therapeutic drug monitoring in psychiatric medication. Biomedical Chromatography, 30, 217–224. https://doi.org/10.1002/bmc.3538

Souri, E., Zargarpoor, M., Mottaghi, S., Ahmadkhaniha, R., & Kebriaeezadeh, A. (2015). A stability‐indicating HPLC method for the determination of fingolimod in pharmaceutical dosage forms. Scientia Pharmaceutica, 83, 85–93. https://doi.org/10.3797/scipharm.1408-08

Suneetha, A., & Rajeswari, K. R. (2016). A high throughput flow gradient LC‐MS/MS method for simultaneous determination of fingolimod, fampridine and prednisone in rat plasma, application to in vivo perfusion study. Journal of Pharmaceutical and Biomedical Analysis, 120, 10–18. https://doi.org/10.1016/j.jpba.2015.11.042

Urinovska, R., Brozmanová, H., Sistik, P., Silhan, P., Kacirova, I., Lemr, K., & Grundmann, M. (2012). Liquid chromatography‐tandem mass spectrometry method for determination of five antidepressants and four atypical antipsychotics and their main metabolites in human serum. Journal of Chromatography B, 907, 101–107. https://doi.org/10.1016/j.jchromb.2012.09.009

van Eeckhaut, A., Lanckmans, K., Sarre, S., Smolders, I., & Michotte, Y. (2009). Validation of bioanalytical LC‐MS/MS assays: Evaluation of matrix effects. Journal of Chromatography B, 877, 2198–2207. https://doi.org/10.1016/j.jchromb.2009.01.003

Zollinger, M., Gschwind, H. P., Jin, Y., Sayer, C., Zécri, F., & Hartmann, S. (2011). Absorption and disposition of the sphingosine 1‐phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: A case of xenobiotic biotransformation following endogenous metabolic pathways. Drug Metabolism & Disposition, 39(2), 199–207. https://doi.org/10.1124/dmd.110.035907